Molecular epidemiology of Clostridium difficile strains from nosocomial-acquired infections
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
- MeSH
- antibakteriální látky farmakologie MeSH
- Clostridioides difficile klasifikace účinky léků genetika izolace a purifikace MeSH
- fenotyp MeSH
- genetická variace MeSH
- genotyp MeSH
- infekce spojené se zdravotní péčí epidemiologie mikrobiologie MeSH
- klostridiové infekce epidemiologie mikrobiologie MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- molekulární epidemiologie MeSH
- molekulární typizace MeSH
- průjem epidemiologie mikrobiologie MeSH
- shluková analýza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- antibakteriální látky MeSH
The purpose of this study is to analyze isolates of Clostridium difficile from patients with nosocomial acquired infection in respect to their molecular type and antimicrobial susceptibility. Fifty-nine randomly selected clinical isolates were characterized. Molecular typing was performed by rep-PCR (DiversiLab). Isolates were tested by disk diffusion towards 11 different antibiotics. All isolates were susceptible to metronidazole and vancomycin. Fifty five (93 %) isolates were resistant to erythromycin and fifty six (95 %) exhibited resistance to both clindamycin and moxifloxacin. Twenty rep-PCR types were identified, but most clinical isolates formed four major rep-PCR clusters (A1 24/59, 40 %; A2 20/59, 33 %; A3 5/59, 8 %; A4 3/59, 5 %). These results show high genetic variability, which demonstrate clearly the complexity of the strains of C. difficile and also show an increasing rate of resistance to fluoroquinolones in our region emphasizing the importance of implementing surveillance programs in order to prevent further spread of resistance in C. difficile.
Zobrazit více v PubMed
J Antimicrob Chemother. 2011 Dec;66 Suppl 6:vi47-56 PubMed
Clin Infect Dis. 2007 Jul 15;45(2):222-7 PubMed
Clin Microbiol Infect. 2011 Feb;17(2):166-75 PubMed
CMAJ. 2004 Aug 31;171(5):466-72 PubMed
J Clin Microbiol. 2006 Feb;44(2):353-8 PubMed
New Microbiol. 2012 Jul;35(3):307-16 PubMed
J Antimicrob Chemother. 2001 Nov;48(5):741-2 PubMed
Antimicrob Agents Chemother. 2006 May;50(5):1890-2 PubMed
Emerg Infect Dis. 2007 Sep;13(9):1417-9 PubMed
Antimicrob Agents Chemother. 2005 Mar;49(3):1157-9 PubMed
Antimicrob Agents Chemother. 2011 Apr;55(4):1701-5 PubMed
J Med Microbiol. 2011 Aug;60(Pt 8):1112-1118 PubMed
J Clin Microbiol. 2000 Jul;38(7):2706-14 PubMed
Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S19-31 PubMed
Ann Intern Med. 1994 Feb 15;120(4):272-7 PubMed
J Clin Microbiol. 2010 Aug;48(8):2892-6 PubMed
N Engl J Med. 2008 Oct 30;359(18):1932-40 PubMed
CMAJ. 2004 Jul 6;171(1):51-8 PubMed
J Med Microbiol. 2008 Jun;57(Pt 6):771-775 PubMed
J Bacteriol. 2010 Oct;192(19):4904-11 PubMed
J Clin Microbiol. 2008 Feb;46(2):431-7 PubMed
J Clin Microbiol. 2002 Jan;40(1):101-4 PubMed
Lancet. 2011 Jan 1;377(9759):63-73 PubMed
Emerg Infect Dis. 2006 Mar;12(3):409-15 PubMed
Ann Intern Med. 1998 Jun 15;128(12 Pt 1):989-95 PubMed
BMC Infect Dis. 2013 Mar 22;13:146 PubMed
Pathol Biol (Paris). 2007 Nov;55(8-9):429-33 PubMed
N Engl J Med. 2005 Dec 8;353(23):2433-41 PubMed
Clin Microbiol Infect. 2007 Nov;13(11):1048-57 PubMed
J Prev Med Hyg. 2009 Jun;50(2):117-20 PubMed
Gastroenterology. 2009 May;136(6):1913-24 PubMed
Clin Microbiol Rev. 2010 Jul;23(3):529-49 PubMed
J Med Microbiol. 2005 Feb;54(Pt 2):149-153 PubMed
Clin Microbiol Infect. 2012 Aug;18(8):E266-72 PubMed
Clin Microbiol Infect. 2013 Jun;19(6):521-7 PubMed
